Eli Lilly stock (US5324571083): Long-term weight loss trial success boosts obesity drug prospects

Eli Lilly and Company announced positive long-term data from two Phase 3 trials on May 12, 2026, demonstrating sustained weight loss for obesity patients switching to its Zepbound drug. The results from the SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN studies were presented at the 33rd European Congress on Obesity and published in peer-reviewed journals, highlighting the drug's ability to meet primary and key secondary endpoints. GuruFocus as of May 12, 2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Eli Lilly & Co.: core business model

Eli Lilly and Company develops and markets pharmaceutical products worldwide, with a focus on areas like diabetes, obesity, immunology, cancer, and neuroscience. The company operates through innovative research and development, leveraging its pipeline of blockbuster drugs such as Mounjaro and Zepbound for GLP-1 receptor agonists targeting metabolic diseases. These therapies address high-demand areas in the US healthcare market, where obesity affects over 40% of adults.

Revenue is driven by a mix of established franchises and new launches, supported by strategic manufacturing expansions in the US to meet surging demand. Eli Lilly's model emphasizes R&D investment, with over $10 billion spent annually on innovation, positioning it as a leader in biotech-driven pharmaceuticals relevant to US investors via NYSE listing.

Main revenue and product drivers for Eli Lilly & Co.

Zepbound (tirzepatide), approved for obesity, has become a key growth driver following strong clinical data. The recent SURMOUNT-MAINTAIN trial showed patients on the maximum tolerated dose (MTD) and 5 mg dose sustained weight loss after 60 weeks of prior treatment, achieving all primary endpoints. This builds on prior quarters where obesity drugs contributed significantly to revenue growth.

Other drivers include Mounjaro for diabetes and oncology products like Verzenio. In Q1 2026, Eli Lilly raised full-year guidance amid momentum in new medicines, with quarterly revenue up sharply year-over-year per recent filings. StockTitan as of May 2026. The stock traded at $780.40 USD on NYSE recently, up 0.97%.

Industry trends and competitive position

The GLP-1 obesity market is exploding, projected to exceed $100 billion by 2030, with Eli Lilly competing against Novo Nordisk's Wegovy. Eli Lilly's tirzepatide offers dual GIP/GLP-1 action, showing superior weight loss in head-to-head data, enhancing its US market share where payers increasingly cover these therapies for chronic weight management.

Why Eli Lilly & Co. matters for US investors

As a NYSE-listed blue-chip pharma with heavy US revenue exposure (over 50%), Eli Lilly benefits from domestic healthcare spending and obesity epidemic trends. Its innovations align with US policy shifts toward preventive care, making it a staple in growth-oriented portfolios tracking biotech advancements.

Conclusion

Eli Lilly's latest trial data underscores Zepbound's potential in the competitive obesity space, supporting ongoing revenue momentum and guidance upgrades. While clinical successes drive optimism, the company faces manufacturing scale-up and competition challenges. Investors monitor upcoming earnings and pipeline updates for sustained performance on NYSE.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.